Related Experiment Videos
Palivizumab: an overview
1Neonatal Unit, St George's Hospital, London.
Hospital Medicine (London, England : 1998)
|March 9, 2000
Insights
Respiratory syncytial virus (RSV) impacts most young children, posing risks to infants. Palivizumab, a new antibody, significantly lowers RSV hospitalizations in high-risk infants when given preventatively.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Respiratory syncytial virus (RSV) is a common childhood infection.
- Severe RSV disease can be life-threatening in at-risk infants.
- Current treatment options and vaccines for RSV are limited.
Purpose of the Study:
- To evaluate the efficacy of palivizumab in preventing RSV-related hospitalizations.
Main Methods:
- A prophylactic regimen of the monoclonal antibody palivizumab was administered throughout the RSV season.
Main Results:
- Palivizumab reduced RSV hospitalization by 55% in at-risk infants.
- This demonstrates significant protection in vulnerable populations.
Conclusions:
- Palivizumab is an effective prophylactic measure against RSV hospitalization in at-risk infants.
- This offers a new strategy for managing RSV in vulnerable populations.
Abstract:
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if given prophylactically throughout the RSV season.